Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.

Innate immune responses to vaccine adjuvants based on lipopolysaccharide (LPS), a component of gram-negative bacterial cell walls, are driven by Toll-like receptor (TLR) 4 and adaptor proteins including MyD88 and TRIF, leading to the production of inflammatory cytokines, type I interferons, and chem...

Full description

Bibliographic Details
Main Authors: Rhea N Coler, Sylvie Bertholet, Magdalini Moutaftsi, Jeff A Guderian, Hillarie Plessner Windish, Susan L Baldwin, Elsa M Laughlin, Malcolm S Duthie, Christopher B Fox, Darrick Carter, Martin Friede, Thomas S Vedvick, Steven G Reed
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3027669?pdf=render
id doaj-beb6c4c5d8824c4a9eada22324c31245
record_format Article
spelling doaj-beb6c4c5d8824c4a9eada22324c312452020-11-24T20:50:02ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0161e1633310.1371/journal.pone.0016333Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.Rhea N ColerSylvie BertholetMagdalini MoutaftsiJeff A GuderianHillarie Plessner WindishSusan L BaldwinElsa M LaughlinMalcolm S DuthieChristopher B FoxDarrick CarterMartin FriedeThomas S VedvickSteven G ReedInnate immune responses to vaccine adjuvants based on lipopolysaccharide (LPS), a component of gram-negative bacterial cell walls, are driven by Toll-like receptor (TLR) 4 and adaptor proteins including MyD88 and TRIF, leading to the production of inflammatory cytokines, type I interferons, and chemokines. We report here on the characterization of a synthetic hexaacylated lipid A derivative, denoted as glucopyranosyl lipid adjuvant (GLA). We assessed the effects of GLA on murine and human dendritic cells (DC) by combining microarray, mRNA and protein multiplex assays and flow cytometry analyses. We demonstrate that GLA has multifunctional immunomodulatory activity similar to naturally-derived monophosphory lipid A (MPL) on murine DC, including the production of inflammatory cytokines, chemokines, DC maturation and antigen-presenting functions. In contrast, hexaacylated GLA was overall more potent on a molar basis than heterogeneous MPL when tested on human DC and peripheral blood mononuclear cells (PBMC). When administered in vivo, GLA enhanced the immunogenicity of co-administered recombinant antigens, producing strong cell-mediated immunity and a qualitative T(H)1 response. We conclude that the GLA adjuvant stimulates and directs innate and adaptive immune responses by inducing DC maturation and the concomitant release of pro-inflammatory cytokines and chemokines associated with immune cell trafficking, activities which have important implications for the development of future vaccine adjuvants.http://europepmc.org/articles/PMC3027669?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Rhea N Coler
Sylvie Bertholet
Magdalini Moutaftsi
Jeff A Guderian
Hillarie Plessner Windish
Susan L Baldwin
Elsa M Laughlin
Malcolm S Duthie
Christopher B Fox
Darrick Carter
Martin Friede
Thomas S Vedvick
Steven G Reed
spellingShingle Rhea N Coler
Sylvie Bertholet
Magdalini Moutaftsi
Jeff A Guderian
Hillarie Plessner Windish
Susan L Baldwin
Elsa M Laughlin
Malcolm S Duthie
Christopher B Fox
Darrick Carter
Martin Friede
Thomas S Vedvick
Steven G Reed
Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.
PLoS ONE
author_facet Rhea N Coler
Sylvie Bertholet
Magdalini Moutaftsi
Jeff A Guderian
Hillarie Plessner Windish
Susan L Baldwin
Elsa M Laughlin
Malcolm S Duthie
Christopher B Fox
Darrick Carter
Martin Friede
Thomas S Vedvick
Steven G Reed
author_sort Rhea N Coler
title Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.
title_short Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.
title_full Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.
title_fullStr Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.
title_full_unstemmed Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.
title_sort development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2011-01-01
description Innate immune responses to vaccine adjuvants based on lipopolysaccharide (LPS), a component of gram-negative bacterial cell walls, are driven by Toll-like receptor (TLR) 4 and adaptor proteins including MyD88 and TRIF, leading to the production of inflammatory cytokines, type I interferons, and chemokines. We report here on the characterization of a synthetic hexaacylated lipid A derivative, denoted as glucopyranosyl lipid adjuvant (GLA). We assessed the effects of GLA on murine and human dendritic cells (DC) by combining microarray, mRNA and protein multiplex assays and flow cytometry analyses. We demonstrate that GLA has multifunctional immunomodulatory activity similar to naturally-derived monophosphory lipid A (MPL) on murine DC, including the production of inflammatory cytokines, chemokines, DC maturation and antigen-presenting functions. In contrast, hexaacylated GLA was overall more potent on a molar basis than heterogeneous MPL when tested on human DC and peripheral blood mononuclear cells (PBMC). When administered in vivo, GLA enhanced the immunogenicity of co-administered recombinant antigens, producing strong cell-mediated immunity and a qualitative T(H)1 response. We conclude that the GLA adjuvant stimulates and directs innate and adaptive immune responses by inducing DC maturation and the concomitant release of pro-inflammatory cytokines and chemokines associated with immune cell trafficking, activities which have important implications for the development of future vaccine adjuvants.
url http://europepmc.org/articles/PMC3027669?pdf=render
work_keys_str_mv AT rheancoler developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant
AT sylviebertholet developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant
AT magdalinimoutaftsi developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant
AT jeffaguderian developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant
AT hillarieplessnerwindish developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant
AT susanlbaldwin developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant
AT elsamlaughlin developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant
AT malcolmsduthie developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant
AT christopherbfox developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant
AT darrickcarter developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant
AT martinfriede developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant
AT thomassvedvick developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant
AT stevengreed developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant
_version_ 1716804947487490048